Share Name Share Symbol Market Type Share ISIN Share Description
North American Banks Fund LSE:NAM London Ordinary Share GB00B15MQH61 ORD USD0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 154.00p 0.00p 0.00p - - - 0 06:32:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -2.8 -0.7 - 5.85

North American Banks Fund Share Discussion Threads

Showing 76 to 93 of 100 messages
Chat Pages: 4  3  2  1
Last Updated: 10/23/2006 Symbol: NAM Exchange: TSX Venture Current Share Price: $0.52 Shares Outstanding: 32.6 million Shares Fully Diluted: 46.5 million 52 Week Range (Lo - Hi): $0.30 - 0.62 Market Capitalization: $16.952 million = = SUBJECT: Toronto Resource Investment Conference Posted By: pyoing Post Time: 9/25/2006 22:28 I attended the conference and listened to the Nam corporate presentation given by Tommy Cheng CEO. Most of what Tommy spoke is already on their website, but there were a few additions that some may find useful. - there will be a NI43-101 due out November. - 2007: 10,000oz. gold to be poured, with an additional 5,000oz. from newly acquired properties. - US. OTC.BB listing is not being considered by NAM, but in the future the company does want to graduate from the Frankfurt onto Hong Kong exchange. - over a $million in the kitty. 2/ SUBJECT: RE: Toronto Resource Investment Conference Posted By: joemanner Post Time: 9/25/2006 22:42 The conference is informative to me as they have some new exciting projects due to have news coming out soon. I found out a new surge on projects on China after reading the Northern Miner issue on the China/ Mongolia. NAM is definitely among one of them as it has featured, not bad for a Company only listed for less than 6 months! 3/ SUBJECT: RE: Toronto Resource Investment Conference Posted By: BillyMiner Post Time: 9/28/2006 15:38 I spoke to the guys at the show as well. NAM has poured 400 oz of gold already from the Majiahe Property and will most likely get about 2000 oz in total from that project this year. As Pyoing said, they will get another 10,000 oz next year. The newly acquired property will also have production. They have an amazing exploration property (Xuefeng Property) with huge potential and they are currently working on a 43-101 for it. I got the feeling that they are also looking at some other properties to acquire as well. This company has awesome potential for the short and long term. Billy
0007 I've got closing prices for NAM going back to 1994 if that's far enough for you. Post your e-mail address and I'll forward it later in the week as I'm incommunicado after 2:30pm for the next 2 days. :-) CM
cat man
has nam been suspended? cant get any quotes on this and no trades.
short zyt has a pe of 60 !! whoops edit. wrong thread :))
time to go short on 5 quid, stop 600
time to go long on 7 quid, stop 550
After the great results and chart breakout the chairmans todger will be some size now..I saY GOOD ON HIM.
brain smiley
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2001 for TCFKANA (The Company Formerly Known as Nycomed Amersham) '.... HIGHLIGHTSSales up 13% to £783 million, earnings per share up 10% to 13.6pImaging sales up 13% to £458 million, driven by growing markets and focus on major disease areasAccelerated growth in portfolio of patented products: sales up 28% to £144 millionGrowth of unpatented products: sales up 10% to £174 millionAmersham Pharmacia Biotech sales up 13% to £325 millionDrug discovery sales up 9% to £71 million: good growth in proteomics, held back by sequencingContinued strong performance in separations, driven by growing sales of biopharmaceuticals and focus on the study of proteins: sales up 22% to £130 million ......'
Does "interesting short" mean "risky short"? :-) I'd be very cautious about calling direction on this one right now - the signals are conflicting!!! The short-term trend (since the last major move, for the purposes of this discussion!) is still up. The intraday high at 571 is just above the 570 of a week ago (same for the closing prices) - this means that there is a good chance of the uptrend continuing until it reaches resistance and there is no reason for this to suddenly reverse. I'd say there is a decent chance of a drop back to 500, but it's equally likely to test resistance again at 580 or even 600. The medium term trend is downward, but given the entire market shot up in 1Q200 and down afterwards, there are few stocks that do not exhibit this pattern. If you think the market, in general, is going down, there are better vehicles to take positions with. Haven't got my annotated charts here, but that's my tuppence worth for now! SpiceBoy
:-) I'm thinking it looks like an interesting short right now. Lower high and all that.
mad mac
MM, are we still on the trading here, or is this one of the "late night confessions" threads! :-) No, out of NAM - I moved my trailing stop in close when it struggled to break through 500. Got taken out on the way up to 522ish at the start of July. Very nice trade for me - the charting was perfect, entered at correct time, used my stops well, got taken out by my trailing stop. Lots of discipline for a change - don't know what went wrong, er right! SpiceBoy
SpiceBoy - you still short?
mad mac
Cheers Brian, not often you get a well done on this BB :-) 500 is such a key level - if it drops below we're into freefall, but if it stays above it should recover. I'm still short but have a tight stop, so worst case I still make a good profit. The Merck p/w can't have helped but an interest rate cut will. Cheers, SpiceBoy
Now it's getting intersting - down she goes!
OK, here's the story of the last 6 weeks from a NAM perspective...nothing - dull, Dull, DULL! Sitting in the range 540ish - 570ish, some days it goes up a bit, some days it goes down a bit! It really needs to move decisively out of this range to indicate a clear direction. I'm still short, but if I wasn't I'd be waiting for a break either way. Really a close above 580 or below 530 would do it for me (although we did open at 581 and reach 586 a few days back, but I generally wait for a close to confirm direction...) Cheers, SpiceBoy
- SB, Agree about failing to break resistance previously, but on the other hand, it's a nice ascending triangle, which it looks to be breaking up out of today. I'd consider a break through 570, and ideally a bounce off it from the other side as pretty positive
now 5.80 and going well.Great company.
brain smiley
NYCOMED AMERSHAM ANNOUNCES FDA CLEARANCE AND LAUNCH OF ECHOSEED 'New Generation of Prostate Brachytherapy Seeds Strengthens Company's Leadership Position in Seed Implant Therapy for Prostate Cancer London, June 4, 2001-Nycomed Amersham (LSE:NAM; NYSE:NYE), the world leader in brachytherapy implants for prostate cancer announced it has received FDA clearance and all other regulatory approvals in the U.S. required to market EchoSeed (Iodine-125), a new generation of brachytherapy seed that will maximize patient care. EchoSeed's patented technology utilizes conventional ultrasound imaging, to provide physicians with more information about seed placement during the course of an implant procedure. "EchoSeed represents the first true breakthrough in brachytherapy treatment since the introduction of RAPID Strand in 1995 and will reinforce Nycomed Amersham's leadership position in the U.S.," said John Jeans, President of Nycomed Amersham Imaging's Therapy Products business. "EchoSeed was developed after feedback from leading practitioners in prostate brachytherapy who wanted more immediate visual information about seed placement during the course of a prostate implant, using currently available imaging technology. Extensive market research among physicians verified EchoSeed's strong market potential," added Mr. Jeans. EchoSeed's patented grooved design in combination with conventional ultrasound imaging allows the physician to view both the prostate gland and EchoSeed during an implant procedure. The physician is able to see more of the seeds during the implant procedure thus facilitating optimal placement into the prostate. EchoSeed will be launched later today at the American Urological Association Annual Meeting in Anaheim, California. Nycomed Amersham is the world leader in brachytherapy implants, used to treat prostate cancer. The company's product portfolio includes OncoSeed, (brand of Iodine-125 prostate brachytherapy seeds) the world's leading prostate implant seed for the treatment of prostate cancer and TheraSeed, the world's leading palladium-103 brachytherapy seed. In addition, the company markets its proprietary RAPID Strand ideally suited for the treatment of extraprostatic extension of prostate cancer; (disease, that affects the area just outside the prostate). ...'
Chat Pages: 4  3  2  1
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180118 22:04:56